ClinicalTrials.gov
public full text
Public Domain
Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1
The goal of this clinical trial is to evaluate a specific antisense oligonucleotide medication in one patient with posterior column ataxia with retinitis pigmentosa. The main question it aims to answer is: what is the safety and tolerability of this medication in a single participant.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)#912780
- Safety of NNC 0123-0000-0338 in Healthy Subjects#1114283
- A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients#902902
- Personalized Antisense Oligonucleotide for Participants With CHCHD10 ALS#893260
- Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS#877951
Record · ID 875533
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive